John O'Reardon, MD. Associate Professor of Psychiatry, University of Pennsylvania Health System.
Dr. O’Reardon has disclosed that he has received research grants from Neuronetics, Cyberonics, Cerex Biopharma, and Pfizer, and is on the speaker's bureaus of Eli Lilly and Bristol-Myers Squibb. Dr. Carlat has found that there is no evidence of commercial bias in this educational activity.
Dr. O’Reardon, the FDA recently approved TMS for depression. Can you clarify exactly what this approval was for?
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.